SCHEMBL14149848

SCHEMBL14149848

CCCCNCc1cccc(Oc2ccc(Cl)cc2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.54
▸ CHRM2 P08172 2/20 0.52
▸ ALDH1A1 P00352 3/20 0.52
▸ KDM4E B2RXH2 3/20 0.52
▸ HTT P42858 2/20 0.52
▸ KMT2A Q03164 2/20 0.50
▸ CYP1A2 P05177 2/20 0.48
▸ CYP2D6 P10635 2/20 0.48
▸ CYP2C19 P33261 2/20 0.48
▸ DRD2 P14416 1/20 0.46
▸ DRD4 P21917 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ PPARG P37231 1/20 0.46
▸ PPARA Q07869 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ THRB P10828 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ HTR1A P08908 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13973310 0.86 ALDH1A1 (0.57) SMN1; SMN2CHRM2ALDH1A1KDM4EHTT
SCHEMBL30821649 0.83 LMNA (0.54) SMN1; SMN2CHRM2ALDH1A1KDM4EHTT
SCHEMBL5947523 0.81 CYP1A2 (0.56) SMN1; SMN2CHRM2ALDH1A1KDM4EHTT
SCHEMBL10106209 0.80 ALDH1A1 (0.56) ALDH1A1DRD2DRD4LMNAPPARG
SCHEMBL13948890 0.80 ALDH1A1 (0.55) SMN1; SMN2ALDH1A1KDM4EHTTKMT2A
SCHEMBL3265492 0.80 CHRM2 (0.79) CHRM2ALDH1A1KDM4EKMT2ACYP1A2
SCHEMBL8493176 0.80 KDM4E (0.64) SMN1; SMN2CHRM2ALDH1A1KDM4EHTT
SCHEMBL5947215 0.80 BCHE (0.62) SMN1; SMN2ALDH1A1KDM4EHTTCYP1A2
SCHEMBL13975775 0.79 CHRM2 (0.77) SMN1; SMN2CHRM2KMT2ACYP1A2CYP2D6
Hydrochloric Acid SCHEMBL27669854 0.79 CHRM2 (0.77) CHRM2ALDH1A1KDM4EKMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9346795-B2 Substituted sulfonamides useful as antiapoptotic Bcl inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2016-05-24 — — US disclosed
US-9346795-B2 Substituted sulfonamides useful as antiapoptotic Bcl inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2016-05-24 — — US disclosed
EP-2714681-B1 SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2015-06-24 — — EP disclosed
EP-2714681-B1 SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2015-06-24 — — EP disclosed
US-20140135318-A1 SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-05-15 — — US disclosed
US-20140135318-A1 SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-05-15 — — US disclosed
WO-2012162365-A1 SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-11-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140135318-A1 SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS BCL2, BAX, BCL2A1 SMN1; SMN2 600/4885CHRM2 4878/4885ALDH1A1 2963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback